Clinical Trials Directory

A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

The purpose of the study was to evaluate the safety and efficacy of the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1 infected adults who had not previously received treatment with antiretroviral medications. Participants were randomized in a 1:1 ratio to receive one of the study treatments. Randomization was stratified by HIV-1 RNA level (? 100,000 copies/mL or > 100,000 copies/mL) at screening. A treatment duration of 96 weeks was planned, with the option for subjects in FTC/RPV/TDF STR arm to receive treatment following the Week 96 visit until FTC/RPV/TDF STR is commercially available or until Gilead Sciences elects to terminate development in that country.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : EFV/FTC/TDF
  • drug : FTC/RPV/TDF

Phase: Phase 3


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Ability to understand and sign a written informed consent form - Plasma HIV-1 RNA levels ? 2,500 copies/mL at screening - No prior use of any approved or experimental anti-HIV drug for any length of time - Screening genotype report showing sensitivity to EFV, FTC, TDF, and lack of the RPV mutations K101E/P, E138A/G/K/Q/R, Y181C/I/V, and H221Y - Normal ECG - Hepatic transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) ? 5 x the upper limit of the normal range (ULN) - Total bilirubin ? 1.5 mg/dL, or normal direct bilirubin - Adequate hematologic function - Serum amylase ? 5 x ULN (participants with serum amylase > 5 x ULN remained eligible if serum lipase was ? 5 x ULN) - Adequate renal function - Males and Females of childbearing potential must have agreed to utilize highly effective contraception methods (two separate forms of contraception, one of which must be an effective barrier method, or be non-heterosexually active, practice sexual abstinence or have a vasectomized partner) from screening throughout the duration of study period and for 12 weeks following the last dose of study drug. - Adult (? 18 years) males or non-pregnant females

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Debbie Slamowitz
(650) 723-2804
Not Recruiting

Footer Links: